Optima II Trial Shows Long-Term Durability of Zusduri in Bladder Cancer
A five-year long-term extension study of the Phase 2b OPTIMA II trial, published in Clinical Genitourinary Cancer, demonstrated durable...
Arrivent’s Pivotal Phase 3 Furvent Data for Firmonertinib Projected Early 2026
ArriVent BioPharma anticipates topline data from its global Phase 3 FURVENT trial in early 2026. The trial is evaluating...
nkgen’s FDA Authorization for Neurodegenerative Disease Treatment
NKGen Biotech has received FDA authorization for an Expanded Access Program (EAP) to explore the use of its cryopreserved,...
Oruka Therapeutics Gets IND Clearance for ORKA-001 Psoriasis Trial
Oruka Therapeutics received FDA clearance for its Investigational New Drug (IND) application to begin the Phase 2a clinical trial,...
Recordati Cuts Document Lifecycle Time by 25% Through Centralized Oversight on Veeva
At the 2025 Veeva R&D and Quality Summit, Luca Manfro, R&D Digital Solutions Manager at Recordati, shared how the...
Sanofi Anticipates a 30% Cost Reduction With Veeva Training System
At the 2025 Veeva R&D and Quality Summit, Sanofi unveiled a transformative approach to study training within clinical operations,...
HeartFlow Plaque Analysis Impacts Coronary Artery Disease Management
Heartflow, Inc. announced positive data from the DECIDE Registry, demonstrating that their AI-powered Heartflow Plaque Analysis led to treatment...
Five Abstracts on SPRINT® PNS at ASPN 2025
SPR Therapeutics presented data at the American Society of Pain & Neuroscience (ASPN) Annual Conference demonstrating the effectiveness of...
Actuate’s Ewing Sarcoma Trial Shows Promise in Pediatric Sarcomas
Actuate Therapeutics has completed Phase 1 of its elraglusib study in pediatric patients with refractory cancers, observing promising results...
Lisata and WarpNine Announce ILSTA Trial Completion & Data
Lisata Therapeutics and WARPNINE Incorporated completed patient enrollment in their Phase 1b/2a iLSTA trial in Australia. The trial evaluates...